| Tbio | Transducin-like enhancer protein 4 |
Transcriptional corepressor that binds to a number of transcription factors. Inhibits the transcriptional activation mediated by PAX5, and by CTNNB1 and TCF family members in Wnt signaling. The effects of full-length TLE family members may be modulated by association with dominant-negative AES. Essential for the transcriptional repressor activity of SIX3 during retina and lens development and for SIX3 transcriptional auto-repression (By similarity).
Comments
| Disease | Target Count |
|---|---|
| Animal Mammary Neoplasms | 136 |
| Disease | Target Count | P-value |
|---|---|---|
| Breast cancer | 3578 | 4.3e-68 |
| lung carcinoma | 2843 | 8.4e-39 |
| chronic lymphosyte leukemia | 204 | 2.3e-04 |
| lung cancer | 4740 | 1.3e-03 |
| invasive ductal carcinoma | 2951 | 2.3e-03 |
| cystic fibrosis | 1696 | 3.1e-03 |
| Polycystic ovary syndrome | 360 | 3.7e-03 |
| colon cancer | 1478 | 5.4e-03 |
| glioblastoma | 5792 | 1.7e-02 |
| primitive neuroectodermal tumor | 3035 | 1.7e-02 |
| atypical teratoid / rhabdoid tumor | 5112 | 1.8e-02 |
| ependymoma | 4679 | 2.3e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Kidney cancer | 2613 | 0.0 | 0.6 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Bipolar Disorder | 666 | 0.0 | 1.7 |
| Disease | log2 FC | p |
|---|---|---|
| atypical teratoid / rhabdoid tumor | 1.300 | 1.8e-02 |
| Breast cancer | -1.400 | 4.3e-68 |
| chronic lymphosyte leukemia | 1.100 | 2.3e-04 |
| colon cancer | -1.400 | 5.4e-03 |
| cystic fibrosis | -1.276 | 3.1e-03 |
| ependymoma | 2.100 | 2.3e-02 |
| glioblastoma | 1.300 | 1.7e-02 |
| invasive ductal carcinoma | -1.100 | 2.3e-03 |
| lung cancer | -1.700 | 1.3e-03 |
| lung carcinoma | -1.900 | 8.4e-39 |
| Polycystic ovary syndrome | -1.447 | 3.7e-03 |
| primitive neuroectodermal tumor | 1.200 | 1.7e-02 |
MIRDLSKMYPQTRHPAPHQPAQPFKFTISESCDRIKEEFQFLQAQYHSLKLECEKLASEKTEMQRHYVMY 1 - 70 YEMSYGLNIEMHKQAEIVKRLNAICAQVIPFLSQEHQQQVVQAVERAKQVTMAELNAIIGQQLQAQHLSH 71 - 140 GHGLPVPLTPHPSGLQPPAIPPIGSSAGLLALSSALGGQSHLPIKDEKKHHDNDHQRDRDSIKSSSVSPS 141 - 210 ASFRGAEKHRNSADYSSESKKQKTEEKEIAARYDSDGEKSDDNLVVDVSNEDPSSPRGSPAHSPRENGLD 211 - 280 KTRLLKKDAPISPASIASSSSTPSSKSKELSLNEKSTTPVSKSNTPTPRTDAPTPGSNSTPGLRPVPGKP 281 - 350 PGVDPLASSLRTPMAVPCPYPTPFGIVPHAGMNGELTSPGAAYAGLHNISPQMSAAAAAAAAAAAYGRSP 351 - 420 VVGFDPHHHMRVPAIPPNLTGIPGGKPAYSFHVSADGQMQPVPFPPDALIGPGIPRHARQINTLNHGEVV 421 - 490 CAVTISNPTRHVYTGGKGCVKVWDISHPGNKSPVSQLDCLNRDNYIRSCRLLPDGRTLIVGGEASTLSIW 491 - 560 DLAAPTPRIKAELTSSAPACYALAISPDSKVCFSCCSDGNIAVWDLHNQTLVRQFQGHTDGASCIDISND 561 - 630 GTKLWTGGLDNTVRSWDLREGRQLQQHDFTSQIFSLGYCPTGEWLAVGMENSNVEVLHVTKPDKYQLHLH 631 - 700 ESCVLSLKFAHCGKWFVSTGKDNLLNAWRTPYGASIFQSKESSSVLSCDISVDDKYIVTGSGDKKATVYE 701 - 770 VIY 771 - 773 //
